Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) – Research analysts at Roth Capital lifted their Q3 2024 earnings estimates for shares of Revelation Biosciences in a note issued to investors on Tuesday, September 24th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.95) per share for the quarter, up from their prior estimate of ($1.59). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($12.46) per share. Roth Capital also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.59) EPS, FY2024 earnings at ($6.44) EPS, FY2025 earnings at ($3.95) EPS, FY2026 earnings at ($4.10) EPS, FY2027 earnings at ($2.48) EPS and FY2028 earnings at $2.30 EPS.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.27.
Revelation Biosciences Price Performance
About Revelation Biosciences
Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
See Also
- Five stocks we like better than Revelation Biosciences
- 3 Stocks to Consider Buying in October
- Is Viking Therapeutics Ready For Another Surge?
- 3 Fintech Stocks With Good 2021 Prospects
- AI Boom and Rate Cuts Boost Utility Stocks: Best Growth Picks
- The Most Important Warren Buffett Stock for Investors: His Own
- Top 3 Homebuilder Stocks to Watch as Rates Drop
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.